Cowen Starts Akcea Therapeutics, Inc. (AKCA) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Stifel Starts Akcea Therapeutics, Inc. (AKCA) at Buy
August 8, 2017 5:21 AM EDTStifel initiates coverage on Akcea Therapeutics, Inc. (NASDAQ: AKCA) with a Buy rating and a price target of $19.00.
Analyst Stephen Willey says that while there may be more stringent patient monitoring requirements expected to accompany Volanesorsen commercialization, he believes the significant... More
BMO Capital Starts Akcea Therapeutics, Inc. (AKCA) at Outperform
August 8, 2017 5:11 AM EDTBMO Capital initiates coverage on Akcea Therapeutics, Inc. (NASDAQ: AKCA) with a Outperform rating and a price target of $25.00.
Analyst Do Kim expects Volanesorsen approval for familial chylomicronemia syndrome (FCS) sometime in H2 2018 and estimates WW peak sales could be $850 million assuming... More
Wells Fargo Starts Akcea Therapeutics, Inc. (AKCA) at Outperform
August 8, 2017 5:09 AM EDTWells Fargo initiates coverage on Akcea Therapeutics, Inc. (NASDAQ: AKCA) with a Outperform rating and a price target of $27.00.
Analyst Jim Birchenough sees a blockbuster opportunity for lead antisense oligonucleotide therapeutic Volanesoren in patients with familial chylomicronemia syndrome (FCS). The analyst believes the... More
